DXCM vs KYMR · P/E 63, rev $2.50B vs rev $99.4M
DexCom Inc (DXCM) versus Kymera Therapeutics Inc (KYMR) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported KYMR revenue for 2026-06-30 was $99.4M. Net income was -$130.4M. KYMR currently screens at market cap $7.39B.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. KYMR currently screens at market cap $7.39B.
Not investment advice. Open the DXCM and KYMR stock pages for the full models.
Not investment advice.